Liver Biopsy Diagnosis of Cirrhosis

  • Zachary D. GoodmanEmail author


Fibrosis in liver disease is the result of an abnormal increase in collagen fibers and other components of the extracellular matrix in response to chronic injury. Progression of chronic liver disease is due to the combined effects of ongoing injury, liver cell death, scarring and regeneration which produce the tissue changes that are termed cirrhosis. Chronic liver diseases progress to cirrhosis through a sequence of morphologic changes that reflect increasing fibrosis and architectural distortion.

Staging systems of varying complexity based on these morphologic changes have been used in patient management as a guide to prognosis and in clinical investigations as an estimate of natural history and response to therapy. Needle biopsy can be used for staging of chronic liver diseases, subject to the limitations of sampling error. Large biopsies produce erroneous results less often than small biopsies.


Fibrosis Cirrhosis Liver biopsy Staging Morphometry 


  1. 1.
    Laennec RTH. Traite de l’Auscultation Mediate, et des Maladies des Poumon et du Coeur. Paris: Chaude; 1819.Google Scholar
  2. 2.
    Smetana HF. The histologic diagnosis of viral hepatitis by needle biopsy. Gastroenterology. 1954;26:612–25.PubMedGoogle Scholar
  3. 3.
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Anthony PP, Ishak KG, Nyak NC, Poulsen HE, Scheuer PJ, Sobin LS. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ. 1977;55:521–40. (reprinted in J Clin Pathol. 1978;31:395–414)PubMedPubMedCentralGoogle Scholar
  5. 5.
    Sherman KE, Goodman ZD, Sullivan ST, Faris-Young S. Liver biopsy in cirrhotic patients. Am J Gastroenterol. 2007;102:789–93.CrossRefPubMedGoogle Scholar
  6. 6.
    Wanless IR. Vascular disorders. In: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, editors. Pathology of the liver. 4th ed. London: Churchill Livingstone; 2002. p. 539–73.Google Scholar
  7. 7.
    Fauerholdt L, Schlichting P, Christensen E, Poulsen H, Tygstrup N, Juhl E. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology. 1983;3:928–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Wanless IR, Nakasimia E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599–607.PubMedGoogle Scholar
  9. 9.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Bedossa P, Bioulac-Sage P, Callard P, Chevallier M, Degott C, Deugnier Y, Fabre M, Reynes M, Voight JJ, Zafrani ES. Interobserver and intraobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20.CrossRefGoogle Scholar
  12. 12.
    Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Ishak KG, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Sachmidt M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim SU, Oh HJ, Wanless IR, Lee S, Han KH, Park YN. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol. 2012;57:556–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009;51:585–94.CrossRefGoogle Scholar
  16. 16.
    Ludwig J, Dickson ER, McDonald GS. Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A. 1978;379:103–12.CrossRefGoogle Scholar
  17. 17.
    Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology. 1981;1:632–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Younossi Z, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for non-alcoholic steatohepatitis (NASH): inter-protocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007;45:886–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C. HALT-C Trial Group: fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009;50:1738–49.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, Webster A, Schultz M, Watson H, Stancil B, Gardner S. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010;138:1365–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Holund B, Poulsen H, Schlichting P. Reproducibility of the liver biopsy diagnosis in relation to the size of the specimen. Scand J Gastroenterol. 1980;15:329–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Schiano TD, Azeem S, Bodian CA, Bodenheimer HC Jr, Merati S, Thung SN, Hytiroglou P. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2005;3:930–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med. 1979;139:667–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Liver Pathology Research and Consultation, Center for Liver DiseasesInova Fairfax HospitalFalls ChurchUSA

Personalised recommendations